Lonza has announced that its newly acquired California biologics manufacturing site is instrumental in driving a significant sales rebound. The company anticipates that sales in the second half of the year will surpass those from the first half, reinforcing its confidence in a robust recovery trajectory.
This strategic acquisition aligns with Lonza’s broader growth strategy, as the firm aims to leverage its expanded capabilities in biologics to meet increasing market demand. By enhancing its production capacity, Lonza is positioned to capitalize on emerging opportunities within the biopharmaceutical sector, particularly as the industry shifts towards more complex biologic therapies.
The implications of this growth are substantial for stakeholders across the pharmaceutical supply chain. With projected revenue growth of 20% to 21% for 2025, this rebound not only reflects Lonza’s operational resilience but also signals a potential uptick in investment and collaboration opportunities within the biologics space.
Use the database as your supply chain compass →
